Company profilePharmaceutical#138 of 1,318 in Pakistan✓ No DRAP alerts

AsianContinental (Pvt.) Ltd.

Pharmaceutical company · 120 brands · 101 molecules

Ranked #74 of 207 companies in Quinolone Antibacterials

120 registered products 56 pharmaceutical brands 101 distinct molecules 0 DRAP alerts

Company overview

120
registered products
56
pharmaceutical brands
101
distinct molecules
12
therapeutic classes
0
DRAP alerts

AsianContinental (Pvt.) Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 120 product registrations across 101 distinct molecules. It is the 138th largest registrant in Pakistan by product count, and ranks 74th of 207 in Quinolone Antibacterials. Its portfolio is concentrated in Quinolone Antibacterials and Blood Glucose Lowering Drugs, Excluding Insulin. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by AsianContinental

125 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

84
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
20257
202677

Top molecules by brand count

Therapeutic classes

Quinolone Antibacterials · 3Blood Glucose Lowering Drugs, Excluding Insulin · 3Antiinflammatory And Antirheumatic Products · 3Cardiac Care · 3Angiotensin-Ii Antagonists, Combinations · 2Other Analgesics And Antipyretics · 2Gastro · 2Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 2Antihistamines For Systemic Use · 2Anti-Infectives · 2Lipid Modifying Agents · 2Opioids · 2

Conditions treated

Ulcer/Reflux/Flatulence/Acidity · 2General Infections · 2High Cholestrol · 2Pain Killers · 1Non-Sedative Agents · 1Bleeding Disorder · 1Hypertension · 1Anaemia · 1Bladder & Prostate Disorder · 1Oral Agents · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official123 products · Rs 23.17 – Rs 12,496.18
DVAGO35 products · Rs 37 – Rs 569.9
Servaid24 products · Rs 52.9 – Rs 750
Median across source: Rs 180.56

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

SEARLE PAKISTAN (PVT.) LTD. holds 203 molecules not in this portfolio
AcetazolamideAdalimumabAlprazolamAmilorideAminophyllineAmitriptyline
GETZ PHARMA PAKISTAN (PVT) LTD. holds 236 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
MEDIATE PHARMACEUTICALS (PVT) LTD holds 85 molecules not in this portfolio
AcyclovirAlendronateAmoxicillinAmpicillinAmpicillin BaseAnastrozole

Get the full profile for AsianContinental

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.